Beyond their glycemic benefits, GLP-1 agonists have garnered attention for their potential protective effects on the cardiovascular system and their role in the management of hepatic diseases, such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)7–14. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.